Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9232548,EC50,"Terfenadine prolonged the QT interval in an infusion-rate-dependent manner, its EC50 value was 792-1039 ng mL-1.",A comparative pharmacokinetic-pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9232548/),[ng] / [ml],792-1039,4936,DB00751,Epinastine
,15606439,C(max),"The result of the application of the PPK model to the clinical trial in paediatric patients, in which dosage was determined based on the body weight (from 14 kg to less than 24 kg; 10 mg dose, 24 kg or more; 20 mg dose), showed that the C(max) and AUC (25.6 +/- 6.9 ng ml(-1) and 246.8 +/- 68.2 ng h ml(-1)) were almost same levels with those of adults after administration of 20 mg (26.9 +/- 9.1 ng ml(-1) and 281.6 +/- 90.5 ng h ml(-1)).","Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606439/),[ng] / [ml],25.6,37370,DB00751,Epinastine
,15606439,C(max),"The result of the application of the PPK model to the clinical trial in paediatric patients, in which dosage was determined based on the body weight (from 14 kg to less than 24 kg; 10 mg dose, 24 kg or more; 20 mg dose), showed that the C(max) and AUC (25.6 +/- 6.9 ng ml(-1) and 246.8 +/- 68.2 ng h ml(-1)) were almost same levels with those of adults after administration of 20 mg (26.9 +/- 9.1 ng ml(-1) and 281.6 +/- 90.5 ng h ml(-1)).","Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606439/),[ng] / [ml],26.9,37371,DB00751,Epinastine
,15606439,AUC,"The result of the application of the PPK model to the clinical trial in paediatric patients, in which dosage was determined based on the body weight (from 14 kg to less than 24 kg; 10 mg dose, 24 kg or more; 20 mg dose), showed that the C(max) and AUC (25.6 +/- 6.9 ng ml(-1) and 246.8 +/- 68.2 ng h ml(-1)) were almost same levels with those of adults after administration of 20 mg (26.9 +/- 9.1 ng ml(-1) and 281.6 +/- 90.5 ng h ml(-1)).","Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606439/),[h·ng] / [ml],246.8,37372,DB00751,Epinastine
,15606439,AUC,"The result of the application of the PPK model to the clinical trial in paediatric patients, in which dosage was determined based on the body weight (from 14 kg to less than 24 kg; 10 mg dose, 24 kg or more; 20 mg dose), showed that the C(max) and AUC (25.6 +/- 6.9 ng ml(-1) and 246.8 +/- 68.2 ng h ml(-1)) were almost same levels with those of adults after administration of 20 mg (26.9 +/- 9.1 ng ml(-1) and 281.6 +/- 90.5 ng h ml(-1)).","Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606439/),[ng] / [ml],26.9,37373,DB00751,Epinastine
,15606439,AUC,"The result of the application of the PPK model to the clinical trial in paediatric patients, in which dosage was determined based on the body weight (from 14 kg to less than 24 kg; 10 mg dose, 24 kg or more; 20 mg dose), showed that the C(max) and AUC (25.6 +/- 6.9 ng ml(-1) and 246.8 +/- 68.2 ng h ml(-1)) were almost same levels with those of adults after administration of 20 mg (26.9 +/- 9.1 ng ml(-1) and 281.6 +/- 90.5 ng h ml(-1)).","Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606439/),[h·ng] / [ml],281.6,37374,DB00751,Epinastine
,11456119,bioavailability,The bioavailability of EPN after oral dosing was 41 and 40%.,Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11456119/),%,41,119277,DB00751,Epinastine
,11456119,bioavailability,The bioavailability of EPN after oral dosing was 41 and 40%.,Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11456119/),%,40,119278,DB00751,Epinastine
,11456119,total biliary excretion,"The total biliary excretion of EPN at a 7.5 mg/kg dose was 15.5% of the dose, but the percentage of conjugates in bile was extremely low and about 11% of the total biliary excretion.",Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11456119/),,15,119279,DB00751,Epinastine
